IPO - Bio-Gene Technology Ltd, page-2

TRANSACTION OVERVIEW
Issuer Bio-Gene Technology Ltd (“Bio-Gene” or the “Company”)
Offer Type Initial Public Offering (“IPO” or the “Offer”)
Lead Manager Henslow Pty Ltd (“Henslow” or the “Lead Manager”)
Offer Closes Friday, 10 November 2017
Offer Price A$0.20 per share Existing Shares 91,224,471 (pre Offer)
Offer Size A$7.0 million New Shares 35,000,000
Market Capitalisation A$25.2 million (post Offer) Shares on Issue 126,224,471 (post Offer)

INVESTMENT HIGHLIGHTS
• Unique (new) mode of action identified – new platform chemistry showing effectiveness against insecticide resistant
pests in a market seeking new products
• Significant test results to date demonstrating effectiveness of FlavocideTM (platform product) at controlling resistant
pests including mosquitoes, flies, fleas, ticks and grain pests
• First global partnership agreement signed with Virbac, a leading global animal health company
• Key collaboration agreements in place with leading institutions
• Manufacturing optimisation well underway with CSIRO to produce FlavocideTM at commercial rates and pricing

COMPANY OVERVIEW
• Bio-Gene is a novel insecticide company
• Technology platform based around a class of chemistry known as Beta-Triketones with initial products, FlavocideTM and
QcideTM shown to be highly effective in insect control management
• Products potentially suitable for commercialisation into multiple targeted insecticides aimed at addressing the global
problem of insecticide resistance across multiple market categories
• Over the next 12 months, continue to form ongoing development partnerships with major AgChem companies

KEY DIRECTORS AND EXECUTIVE TEAM
Don Brumley
Non-Exec. Chairman
• 25+ years as a senior partner and leader of Ernst & Young – Oceania


Richard Jagger
Executive Director &
CEO - Elect
• 25+ years working in agriculture, most recently as Managing Director of Sinochem Australia
• Previously spent 15+ years at Monsanto (Bayer) in various management roles

Robert Klupacs
Executive Director
• 30+ years of corporate experience in international technology development, previously as MD
& CEO of ASX-listed Circadian Technologies Limited
• Registered Australian patent attorney

Douglas Rathbone
Advisor to the Board
• 40+ years experience in the agricultural sector, most recently as Managing Director of Nufarm
Ltd, a position he held for 15+ years
• Under his leadership, Nufarm Ltd grew to be one of Australia’s most successful agricultural
companies with global sales >$2.5B

Roger McPherson
CFO & Co-Sec
• 15+ years experience as a CFO across the Pharma, Biotech and Biopharmaceuticals fields
• Previously, CFO and Co-Sec of TPI Enterprises (ASX:TPI)